Cargando…
Dihydroartemisinin protects blood–brain barrier permeability during sepsis by inhibiting the transcription factor SNAI1
Blood–brain barrier (BBB) injury is involved in the pathogenesis of sepsis‐associated encephalopathy. In this study, we used dihydroartemisinin (DHA), a derivative of artemisinin, to treat a cecal ligation and puncture (CLP)‐induced mouse sepsis model and a tumour necrosis factor α (TNF‐α)‐stimulate...
Autores principales: | Liu, Fuhong, Liu, Jing, Xiang, Hongjie, Sun, Zongguo, Li, Yan, Li, Xiao, Liu, Yanjun, Liu, Ju |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9543489/ https://www.ncbi.nlm.nih.gov/pubmed/35651290 http://dx.doi.org/10.1111/1440-1681.13683 |
Ejemplares similares
-
Dihydroartemisinin inhibits the expression of von Willebrand factor by downregulation of transcription factor ERG in endothelial cells
por: Dong, Fengyun, et al.
Publicado: (2020) -
SNAI1 recruits HDAC1 to suppress SNAI2 transcription during epithelial to mesenchymal transition
por: Sundararajan, Vignesh, et al.
Publicado: (2019) -
miR-539 Targeting SNAI2 Regulates MMP9 Signaling Pathway and Affects Blood-Brain Barrier Permeability in Cerebrovascular Occlusive Diseases: A Study Based on Head and Neck Ultrasound and CTA
por: Li, Hui, et al.
Publicado: (2021) -
Liver X receptor alpha ensures blood-brain barrier function by suppressing SNAI2
por: Vacondio, D., et al.
Publicado: (2023) -
Dihydroartemisinin inhibits endothelial cell migration via the TGF-β1/ALK5/SMAD2 signaling pathway
por: Guo, Ling, et al.
Publicado: (2021)